Cargando…
P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
Autores principales: | Taszner, Michał, Luminari, Stefano, Cho, Seok-Goo, Novelli, Silvana, Le Gouill, Steven, Poon, Michelle, Villasboas, Jose, Champion, Rebecca, Bachy, Emmanuel, Guidez, Stephanie, Alonso Alonso, Aránzazu, Jagadeesh, Deepa, Merli, Michele, Tucker, David, Cai, Jingxian, Leite de Oliveira, Carolina, Zhu, Min, Chaudhry, Aafia, Mohamed, Hesham, Ambati, Srikanth, Min Kim, Tae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431020/ http://dx.doi.org/10.1097/01.HS9.0000971228.21453.6e |
Ejemplares similares
-
P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
por: Walewski, Jan, et al.
Publicado: (2023) -
PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY
por: Cho, Seok-Goo, et al.
Publicado: (2023) -
PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
por: Novelli, Silvana, et al.
Publicado: (2023) -
PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023) -
PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)
por: Luminari, Stefano, et al.
Publicado: (2023)